Cargando…
Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy
Ovarian cancer is the deadliest of all gynecologic malignancies claiming the lives of nearly 14,000 women in the United States annually. Despite therapeutic advances, the ovarian cancer mortality rate has remained stagnant since the 1980’s. The molecular heterogeneity of ovarian cancers suggest they...
Autores principales: | Harbin, Laura M., Gallion, Holly H., Allison, Derek B., Kolesar, Jill M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030726/ https://www.ncbi.nlm.nih.gov/pubmed/35453890 http://dx.doi.org/10.3390/diagnostics12040842 |
Ejemplares similares
-
MUTYH as an Emerging Predictive Biomarker in Ovarian Cancer
por: Hutchcraft, Megan L., et al.
Publicado: (2021) -
SYNE1 Mutation Is Associated with Increased Tumor Mutation Burden and Immune Cell Infiltration in Ovarian Cancer
por: Harbin, Laura M., et al.
Publicado: (2023) -
Utilizing Patient-Derived Epithelial Ovarian Cancer Tumor Organoids to Predict Carboplatin Resistance
por: Gorski, Justin W., et al.
Publicado: (2021) -
Targeted next generation sequencing for molecular diagnosis of Usher syndrome
por: Aparisi, María J, et al.
Publicado: (2014) -
Genomics in 2012: challenges and opportunities in the next generation sequencing era
por: Zhao, Zhongming, et al.
Publicado: (2012)